Loading…
Cancer Care Payment Reform Act of 2017
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 3,805 other S bills in the 115th — cohort avg 41d
Cancer Care Payment Reform Act of 2017 This bill amends title XVIII (Medicare) of the Social Security Act to establish the Oncology Medical Home Demonstration Project, through which the Centers for Medicare & Medicaid Services (CMS) shall make special payments to participating oncology practices that coordinate patient care and meet other specified requirements. During the first two years of the project, CMS shall pay a care coordination management fee to each such practice. After the third, fourth, and fifth years of the project, CMS shall pay a performance incentive payment to each participating practice that meets or exceeds performance standards developed by CMS. CMS shall assess the performance of each participating oncology practice annually. Performance standards shall address: (1) specified measures related to patient care, resource utilization, survivorship, and end-of-life care; and (2) the patient experience of care, as reflected in surveys submitted by each practice. CMS shall also assess the extent to which a practice has used breakthrough or other best-in-class therapies. To the extent practicable, CMS shall select practices of varying sizes and geographic areas for participation.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (5)
2018 · fourth_quarter · Medicare/Medicaid
Read twice and referred to the Committee on Finance. (text of measure as introduced: CR S1502-1504)
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Medicare Part D Coverage and Reimbursement Medicare Part D Non-Interference Legislative proposals to change Medicare Part D Medicare Part B coverage and reimbursement Medicaid Coverage Coverage Gap Discount Cancer Care Payment Reform Act (S 463, H 1834) Oncology Care Model - CMS Medicaid Rebate issues
Client expense: $810,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2018 · third_quarter · Medicare/Medicaid
Medicare Part D Coverage and Reimbursement Medicare Part D Non-Interference Legislative proposals to change Medicare Part D Medicare Part B coverage and reimbursement Medicaid Coverage Coverage Gap Discount Cancer Care Payment Reform Act (S 463, H 1834) Oncology Care Model - CMS
Client expense: $620,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2018 · fourth_quarter · Medicare/Medicaid
H.R. 6836, the CLINICAL TREATMENT Act H.R. 4841, the Standardizing Electronic Prior Authorization for Safe Prescribing Act H.R.1834/S. 463 - Cancer Care Payment Reform Act of 2017 Implementation of Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) Implementation of Protecting Access to Medicare Act of 2014 (PAMA)
Client expense: $79,366 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · fourth_quarter · Medicare/Medicaid
Medicare Part D Coverage and Reimbursement Medicare Part D Non-Interference Legislative proposals to change Medicare Part D Medicare Part B coverage and reimbursement Medicaid Coverage Coverage Gap Discount Cancer Care Payment Reform Act (S 463, H 1834) Oncology Care Model - CMS Medicaid Rebate issues
Client expense: $810,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2018 · third_quarter · Medicare/Medicaid
H.R. 6836, the CLINICAL TREATMENT Act H.R. 4841, the Standardizing Electronic Prior Authorization for Safe Prescribing Act H.R.1834/S. 463 - Cancer Care Payment Reform Act of 2017 Implementation of Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) Implementation of Protecting Access to Medicare Act of 2014 (PAMA)
Client expense: $223,857 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · third_quarter · Medicare/Medicaid
Medicare Part D Coverage and Reimbursement Medicare Part D Non-Interference Legislative proposals to change Medicare Part D Medicare Part B coverage and reimbursement Medicaid Coverage Coverage Gap Discount Cancer Care Payment Reform Act (S 463, H 1834) Oncology Care Model - CMS
Client expense: $510,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2018 · second_quarter · Medicare/Medicaid
H.R. 4841, the Standardizing Electronic Prior Authorization for Safe Prescribing Act H.R.1834/S. 463 - Cancer Care Payment Reform Act of 2017 Implementation of Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) Implementation of Protecting Access to Medicare Act of 2014 (PAMA)
Client expense: $62,560 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · second_quarter · Health Issues
American Health Care Act (HR 1628 House) SYNC Act - Medication Adherence (House) Value of Prescription Drugs Chronic Care - Druge Adherence and Continuity of Care (S 870) Price Transparency Oncology Oncology Care Model - CMS Personalized Medicine Affordable and Safe Prescription Drug Importation Act - S 469 Cancer Care Payment Reform Act (S 463, H 1834) Vaccines for Children program
Client expense: $460,000 · Firm income: Not reported
2018 · first_quarter · Medicare/Medicaid
- Medicare prompt pay discount exclusion, including legislation to ensure appropriate reimbursement for drugs and biologics under Medicare Part B by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's Average Sales Price (ASP) (H.R. 1920); ASP, generally (in the context of Deficit Reduction) - Legislation to exclude cancer drugs from sequestration cuts; Cancer Care Payment Reform Act (H.R. 1834/S. 463)
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · first_quarter · Health Issues
American Health Care Act (HR 1628 House) SYNC Act - Medication Adherence (House) Value of Prescription Drugs Chronic Care - Druge Adherence and Continuity of Care (S 870) Price Transparency Oncology Oncology Care Model - CMS Personalized Medicine Affordable and Safe Prescription Drug Importation Act - S 469 Cancer Care Payment Reform Act (S 463, H 1834) Innovative Payments Vaccines for Children program
Client expense: $600,000 · Firm income: Not reported
2018 · first_quarter · Medicare/Medicaid
H.R.1834/S. 463 - Cancer Care Payment Reform Act of 2017 Implementation of Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) Implementation of Protecting Access to Medicare Act of 2014 (PAMA)
Client expense: $37,103 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · first_quarter · Medicare/Medicaid
Stopping the application of the sequester cut (current and new) to Medicare Part B drug reimbursement (no bill). Fixing the 340B drug discount program, including PAUSE Act (H.R. 4710, HELP Act (S. 2312, and Ensuring the Value of the 340B Program Act (S. 2453) Fixing Medicare Part B drug reimbursement by eliminating the manufacturer-to-wholesaler prompt pay discount from the calculation of average sales price, the basis of Part B drug reimbursement (H.R. 1920, S. 1304). Misc. issues dealing with pharmacy benefit managers and patient and pharmacy abuses (includes bills H.R 1316 - Prescription Drug Price Transparency Act and H.R.1038 - Improving Transparency and Accuracy in Medicare Part D Spending Act}. Medicare oncology payment reform (includes bills S. 463 - Cancer Care Payment Reform Act of 2017 and H.R. 1834 - Cancer Care Payment Reform Act of 2017. Oncology Care Model (CMS/CMMI; no bill). VA clawback of payments made to community oncology practices for treating veterans out of network.
Client expense: $145,500 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
2017 · fourth_quarter · Medicare/Medicaid
H.R.1834/S. 463 - Cancer Care Payment Reform Act of 2017 Implementation of Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) Implementation of Protecting Access to Medicare Act of 2014 (PAMA)
Client expense: $121,530 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · fourth_quarter · Medicare/Medicaid
- Medicare prompt pay discount exclusion, including legislation to ensure appropriate reimbursement for drugs and biologics under Medicare Part B by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's Average Sales Price (ASP) (H.R. 1920); ASP, generally (in the context of Deficit Reduction) - Legislation to exclude cancer drugs from sequestration cuts; Cancer Care Payment Reform Act (H.R. 1834/S. 463)
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · fourth_quarter · Medicare/Medicaid
Stopping the application of the sequester cut (current and new) to Medicare Part B drug reimbursement (no bill). Fixing the 340B drug discount program (no bill). Fixing Medicare Part B drug reimbursement by eliminating the manufacturer-to-wholesaler prompt pay discount from the calculation of average sales price, the basis of Part B drug reimbursement (H.R. 1920, S. 1304). Misc. issues dealing with pharmacy benefit managers and patient and pharmacy abuses (includes bills H.R 1316 - Prescription Drug Price Transparency Act and H.R.1038 - Improving Transparency and Accuracy in Medicare Part D Spending Act}. Medicare oncology payment reform (includes bills S. 463 - Cancer Care Payment Reform Act of 2017 and H.R. 1834 - Cancer Care Payment Reform Act of 2017. Oncology Care Model (CMS/CMMI; no bill).
Client expense: $187,500 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
2017 · fourth_quarter · Health Issues
American Health Care Act (HR 1628 House) SYNC Act - Medication Adherence (House) Value of Prescription Drugs Chronic Care - Druge Adherence and Continuity of Care (S 870) Price Transparency Oncology Oncology Care Model - CMS Personalized Medicine Affordable and Safe Prescription Drug Importation Act - S 469 Cancer Care Payment Reform Act (S 463, H 1834)
Client expense: $620,000 · Firm income: Not reported
2017 · third_quarter · Medicare/Medicaid
- Medicare prompt pay discount exclusion, including legislation to ensure appropriate reimbursement for drugs and biologics under Medicare Part B by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's Average Sales Price (ASP) (H.R. 1920); ASP, generally (in the context of Deficit Reduction) - Legislation to exclude cancer drugs from sequestration cuts; Cancer Care Payment Reform Act (H.R. 1834/S. 463)
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · third_quarter · Medicare/Medicaid
H.R. 1920 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Policies to exclude cancer drugs from the sequestration cuts. H.R. 1834 & S. 463, The Cancer Care Payment Reform Act of 2017. CMS, OMB, HHS, White House Domestic Policy Council, Medicare Part B Reimbursement, Medicare Part D Pharmacy Reimbursement.
Client expense: $330,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · third_quarter · Medicare/Medicaid
H.R.1834/S. 463 - Cancer Care Payment Reform Act of 2017 Implementation of Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) Implementation of Protecting Access to Medicare Act of 2014 (PAMA)
Client expense: $159,919 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · third_quarter · Health Issues
American Health Care Act (HR 1628 House) SYNC Act - Medication Adherence (House) Value of Prescription Drugs Chronic Care - Druge Adherence and Continuity of Care (S 870) Price Transparency Oncology Oncology Care Model - CMS Personalized Medicine Affordable and Safe Prescription Drug Importation Act - S 469 Cancer Care Payment Reform Act (S 463, H 1834)
Client expense: $339,000 · Firm income: Not reported
2017 · third_quarter · Medicare/Medicaid
Application of the sequester cut to Medicare Part B drug reimbursement (no bill). Fixing the 340B drug discount program (no bill). Fixing Medicare Part B drug reimbursement by eliminating the manufacturer-to-wholesaler prompt pay discount from the calculation of average sales price, the basis of Part B drug reimbursement (H.R. 1920, S. 1304). Misc. issues dealing with pharmacy benefit managers and patient and pharmacy abuses (includes bills H.R 1316 - Prescription Drug Price Transparency Act and H.R.1038 - Improving Transparency and Accuracy in Medicare Part D Spending Act. Medicare oncology payment reform (includes bills S. 463 - Cancer Care Payment Reform Act of 2017 and H.R. 1834 - Cancer Care Payment Reform Act of 2017. Oncology Care Model (CMS/CMMI; no bill).
Client expense: $111,500 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
2017 · second_quarter · Medicare/Medicaid
H.R.1834/S. 463 - Cancer Care Payment Reform Act of 2017
Client expense: $76,973 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · second_quarter · Medicare/Medicaid
Application of the sequester cut to Medicare Part B drug reimbursement (no bill). Fixing the 340B drug discount program (no bill). Fixing Medicare Part B drug reimbursement by eliminating the manufacturer-to-wholesaler prompt pay discount from the calculation of average sales price, the basis of Part B drug reimbursement (H.R. 1920, S. 1304). Misc. issues dealing with pharmacy benefit managers and patient and pharmacy abuses (includes bills H.R 1316 - Prescription Drug Price Transparency Act and H.R.1038 - Improving Transparency and Accuracy in Medicare Part D Spending Act. Medicare oncology payment reform (includes bills S. 463 - Cancer Care Payment Reform Act of 2017 and H.R. 1834 - Cancer Care Payment Reform Act of 2017. Oncology Care Model (CMS/CMMI; no bill).
Client expense: $118,800 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2017 · second_quarter · Medicare/Medicaid
- Medicare prompt pay discount exclusion, including legislation to ensure appropriate reimbursement for drugs and biologics under Medicare Part B by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's Average Sales Price (ASP) (H.R. 1920); ASP, generally (in the context of Deficit Reduction). - Legislation to exclude cancer drugs from sequestration cuts; Cancer Care Payment Reform Act (H.R. 1834/S. 463)
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · second_quarter · Medicare/Medicaid
H.R. 1920 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Policies to exclude cancer drugs from the sequestration cuts. H.R. 1834 & S. 463, The Cancer Care Payment Reform Act of 2017. CMS, OMB, HHS, White House Domestic Policy Council, Medicare Part B Reimbursement, Medicare Part D Pharmacy Reimbursement.
Client expense: $310,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · first_quarter · Medicare/Medicaid
H.R.1834/S. 463 - Cancer Care Payment Reform Act of 2017
Client expense: $115,230 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · first_quarter · Medicare/Medicaid
H.R. 1920 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Policies to exclude cancer drugs from the sequestration cuts. H.R. 1834 & S. 463, The Cancer Care Payment Reform Act of 2017.
Client expense: $350,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · first_quarter · Medicare/Medicaid
Application of the sequester cut to Medicare Part B drug reimbursement (no bill). Fixing the 340B drug discount program (no bill). Fixing Medicare Part B drug reimbursement by eliminating the manufacturer-to-wholesaler prompt pay discount from the calculation of average sales price, the basis of Part B drug reimbursement (no bill). Misc. issues dealing with pharmacy benefit managers and patient and pharmacy abuses (includes bills H.R 1316 - Prescription Drug Price Transparency Act and H.R.1038 - Improving Transparency and Accuracy in Medicare Part D Spending Act. Medicare oncology payment reform (includes bills S. 463 - Cancer Care Payment Reform Act of 2017 and H.R. 1834 - Cancer Care Payment Reform Act of 2017. Oncology Care Model (CMS/CMMI; no bill).
Client expense: $124,800 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE